111In-Pentetreotide uptake in a follicular adenoma of the thyroid gland: A pitfall for111In-Pentetreotide scintigraphy

Revista Espanola de Medicina Nuclear

Volumn 25, Issue 5, 2006, Pages 316-319

  Yüksel, Mammut ^a,c   Eziddin, S ^b   Wardelmann, E ^b   Biersack, H Juergen ^b  

^a TRAKYA UNIVERSITY   (Turkey)

^b UNIVERSITY OF BONN   (Germany)

^c TRAKYA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

111In Pentetreotide; Thyroid adenoma

Indexed keywords

PENTETREOTIDE IN 111; PERTECHNETIC ACID TC 99M; SOMATOSTATIN RECEPTOR; CHROMOGRANIN A; DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDIUM; PENTETREOTIDE; RADIOPHARMACEUTICAL AGENT; SEROTONIN; SOMATOSTATIN; THYROGLOBULIN; TUMOR PROTEIN;

ADULT; ARTICLE; CASE REPORT; DRUG UPTAKE; HUMAN; IMAGE ANALYSIS; MALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID ADENOMA; THYROID FOLLICLE CELL; THYROID GLAND; THYROID SCINTISCANNING; ADENOMA; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; LABORATORY DIAGNOSIS; METABOLISM; METASTASIS; MIDDLE AGED; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; THYROID TUMOR;

ADENOMA; CHROMOGRANIN A; DIAGNOSIS, DIFFERENTIAL; FALSE POSITIVE REACTIONS; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SEROTONIN; SOMATOSTATIN; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 33750219757     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1157/13092699     Document Type: Article

References (18)

1. 3]-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med. 1993;20:716-31.
2. 111In-Octreotide scintigraphy. Nucl Med. 1995;34:100-3.
3. 111-octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131. J Cancer Res Clin Oncol. 2003;129:287-94.
4. Gorges R, Kaun M, Frilling A, Schmid KW. Recurrence of a renal cell carcinoma mimicking a multiple endocrine neoplasia with thyroid gland involvement. Nuklearmedizin. 2002;41: N24-6.
5. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scintigraphy. In: Freeman LM, editor. Nuclear Medicine Annual. New York: Raven Press; 1995. p. 1-50.
6. 111 Pentetreotide by normally functioning nodular goiters. Clin Nucl Med. 1997;22:625-7.
7. Gibril F, Reynolds JC, Chen CC, Yu F, Goebel SU, Serrano J, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med. 1999;40:539-53.
8. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med. 2002;32:84-91.
9. Ahren B, Ericson M, Hedner P, Ingemansson S, Westgren U. Somatostatin inhibits thyroid hormone secretion induced by exogenous TSH in man. J Clin Endocrinol Metab. 1978;47:1156-9.
10. Siperstein AE, Levin KE, Gum ET, Clark OH. Effect of somatostatin on adenylate cyclase activity in normal and neoplastic thyroid tissue. World J Surg. 1992;16:555-60.
11. Degli Uberti EC, Hanau S, Rossi R, Piva R, Margutti A, Trasforini G, et al. Somatostatin reduces 3H-thymidine incorporation and c-myc, but not thyroglobulin ribonucleic acid levels in human thyroid follicular cells in vitro. J Clin Endocrinol Metab. 1991;72:1364-71.
12. Tsuzaki S, Moses AC. Somatostatin inhibits deoxyribonucleic acid synthesis induced by both thyrotropin and insulin-like growth factor-I in FRTL5 cells. Endocrinology. 1990;126:3131-8.
13. Ain KB, Taylor KD. Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. J Clin Endocrinol Metab. 1994;78:1097-102.
14. Hoelting T, Duh QY, Clark OH, Herfarth C. Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo. J Clin Endocrinol Metab. 1996;81: 2638-41.
15. Ain KB, Taylor KD, Tofiq S, Venkaraman G. Somatostatin receptor subtypes expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab. 1997;82:1857-62.
16. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med. 2000;41:636-42.
17. Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, Degli Uberti EC. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J Clin Endocrinol Metab. 2001;86:2161-9.
18. Tisel LE, Ahlman H, Wängberg B, Kölby L, Fjälling M, Forssell-Aronsson E, et al. Expression of somatostatin receptors in oncocytic (Hürthle cell) neoplasia of the thyroid. Br J Cancer. 1999;79:1579-82.